Akero Therapeutics Stock Doubles on Liver Data
The data appeared to slam the door on the idea that the advent of GLP-1 drugs would eliminate demand for drugs specifically intended to treat MASH.
Liver Disease-Focused Akero Therapeutics Stock Soars Over 100% On Monday - Here's Why
Akero's SYMMETRY Phase 2b study showed 50mg EFX achieved 24% cirrhosis reversal in MASH patients, with improvements in liver fibrosis and safety.
Akero's stock doubles as midphase MASH trial generates 'transformational' data: analyst
Akero Therapeutics has hit a home run, reporting statistically significant results in two key 96-week metabolic dysfunction-associated steatohepatitis (MASH) analyses to send its stock up about 100%. Analysts with Evercore ISI hailed the data as "transformational" in a note to investors.
Akero soars as drug shows it reverses scarring in liver disease patients
By Sriparna Roy (Reuters) -Akero Therapeutics shares gained 106% before the bell on Monday, after its lead drug showed it can help patients with a type of liver disease to reverse scarring of the organ without worsening the condition in a keenly awaited mid-stage trial.
Akero Therapeutics Stock Doubles on Liver Disease Drug Trial Results
Akero Therapeutics shares traded near their all-time high as the drugmaker reported positive results in a study of its treatment for liver disease.
Akero: Reversal Of Cirrhosis With EFX Is A 'First' In F4 MASH Patients
Akero Therapeutics reports a 39% improvement in cirrhosis patients using EFX. See why AKRO stock is soaring with the breakthrough Phase 2b SYMMETRY data.
biopharma-reporter2d
Akero Therapeutics succeeds with MASH liver treatment at phase 2
Akero Therapeutics announced statistically significant results from a Phase 2b trial of efruxifermin this week, a fibroblast ...
STAT3d
Akero drug reverses liver scarring in study of severe MASH patients
Akero reported Monday strong results showing its drug efruxifermin reversed liver scarring in patients with cirrhosis caused ...
The Pharma Letter2d
Akero Thera rockets on positive MASH results
US clinical-stage liver disease focused biotech Akero Therapeutics saw its shares almost double to $51.71 yesterday, after it ...
Some Good MASH/NASH News From Akero Therapeutics
Akero Therapeutics (AKRO) reported 96-week data in its trial of advanced MASH patients, and there seem really significant ...
STAT23h
MASH drugs reach a meaningful tipping point for patients and investors
Akero's success in reversing cirrhosis follows that of Madrigal, making analysts and investors bullish on drugs to treat ...
Zacks.com on MSN1d
AKRO Stock Doubles in a Week as Lead Drug Meets Goal in MASH Study
Akero stock soars 106% in a week following initial positive top line 96-week data from a mid-stage MASH study of its lead ...
Best, worst of biotech times: One company soars, another stumbles and a third seeks funds
It was the best of biotech times, it was the worst of biotech times: One company soars, another stumbles and a third outlines ...